Gene Therapy Company Announces Positive Results For Geographic Atrophy Treatment
A New Dawn in the Treatment of Geographic Atrophy: Ocugen's OCU410 Shows Promising Early Results.
In a landmark announcement on April 5, 2024, Ocugen, Inc., a pioneer in gene and cell therapies, has taken a significant step forward in the fight against Geographic Atrophy (GA), a severe form of age-related macular degeneration that leads to blindness. The Data and Safety Monitoring Board (DSMB) for the Phase 1/2 ArMaDa clinical trial has green-lighted the continuation to medium dosing of OCU410, marking a pivotal advancement in the development of this innovative gene therapy. $Ocugen(OCGN.US$
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
